The human leukemia oncogene bcr-abl abrogates the anchorage requirement but not the growth factor requirement for proliferation
about
Role for Lyn tyrosine kinase as a regulator of stress-activated protein kinase activity in response to DNA damageThe product of the cbl oncogene forms stable complexes in vivo with endogenous Crk in a tyrosine phosphorylation-dependent mannerNucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicityNovel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571.CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cellsThe Abl-related gene (Arg) nonreceptor tyrosine kinase uses two F-actin-binding domains to bundle F-actinInhibition of c-Abl tyrosine kinase activity by filamentous actin.Bcr-Abl with an SH3 deletion retains the ability To induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancyAn intramolecular SH3-domain interaction regulates c-Abl activity.Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation.Translocations, cancer and the puzzle of specificity.The carboxyl terminus of v-Abl protein can augment SH2 domain function.Growth factor activation of MAP kinase requires cell adhesion.Biological response to phorbol ester determined by alternative G1 pathways.The extreme carboxyl terminus of v-Abl is required for lymphoid cell transformation by Abelson virus.Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies.Ski acts as a co-repressor with Smad2 and Smad3 to regulate the response to type beta transforming growth factorCellular aging is a critical determinant of primary cell resistance to v-src transformation.Integrins, oncogenes, and anchorage independence.Inactivation of pRB-related proteins p130 and p107 mediated by the J domain of simian virus 40 large T antigen.Regulation of transforming growth factor beta- and activin-induced transcription by mammalian Mad proteinsIntegrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport.Adhesion to fibronectin stimulates proliferation of wild-type and bcr/abl-transfected murine hematopoietic cells.The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation.BCR/ABL directly inhibits expression of SHIP, an SH2-containing polyinositol-5-phosphatase involved in the regulation of hematopoiesis.BCR/ABL induces multiple abnormalities of cytoskeletal function.PTPROt inactivates the oncogenic fusion protein BCR/ABL and suppresses transformation of K562 cellsInhibition of the Raf-1 kinase by cyclic AMP agonists causes apoptosis of v-abl-transformed cellsRole of the C-terminal actin binding domain in BCR/ABL-mediated survival and drug resistance.A coiled-coil tetramerization domain of BCR-ABL is essential for the interactions of SH2-containing signal transduction molecules.Cells arrested in G1 by the v-Abl tyrosine kinase do not express cyclin A despite the hyperphosphorylation of RB.The effect of interferon-alpha on beta-1 integrin mediated adhesion and growth regulation in chronic myelogenous leukemia.Reduced focal adhesion kinase and paxillin phosphorylation in BCR-ABL-transfected cells.The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1.Polarized distribution of Bcr-Abl in migrating myeloid cells and co-localization of Bcr-Abl and its target proteins.Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival.Activation of SAPK/JNK signaling by protein kinase Cdelta in response to DNA damage.
P2860
Q22254596-7977FAA1-E2DB-4118-809A-419DF6EC3436Q24310761-D34FAD4C-F062-4118-9A62-ECC809FBB2E5Q24522838-1435FC36-CAC6-465C-8FA7-83767945C621Q27824789-A1FE46E7-B2FD-477B-92AC-D1D680DDFB0DQ28284723-9C1C832B-D170-4BA6-A831-CE75E72CD38DQ28508973-A4A988FF-2CF2-4AFE-8CAB-FF053CE82F28Q30168272-7E1BDC62-7490-41D3-9F01-3442639DAD03Q30175351-BF3E0256-F41E-4B22-873A-72DCECE87D6DQ30176270-A92F13D7-7099-4BD2-9CAD-DDA469CE85D1Q30192925-B2170968-ED1A-4D0E-9C6A-D3EF5E516AF4Q33368676-B0B3C9F0-58F3-4BAC-B81B-201200BAA7CEQ33804134-8ACDD325-239C-49A4-9A21-06216B2396A4Q33887464-00B7715A-6E16-4675-A6F4-4FFCD20C565AQ34263917-0D19E90E-CC04-419F-B54F-16021B05F5FDQ34859191-FB0A5329-1EA0-43D8-A3FD-82A46F1C057DQ35166848-38EF14F6-43BF-4F5A-860C-0C990DAF561CQ35754725-850F305C-214F-4850-930B-AD9914EFB114Q35874837-23FC7A6D-E50E-4038-BD23-D70516699D5DQ36276579-36032858-73CB-4C3F-895F-CD5E4A9C0A36Q36571152-A70D0E8C-DA1C-4F70-AE09-27315757E4BDQ36686570-0F677C6E-3CF6-4BE2-BFEE-A3690B126D0FQ37087928-6F13D482-EA96-49FB-BBFF-8F4AA47B0A43Q37171535-6C2AF665-8550-4457-9F3F-261D13FD9932Q37178213-82AE9A69-1010-451D-BD38-0E0B7893D0CCQ39448485-C2B71808-93A6-439D-9EBF-4644D24A976BQ39786673-639C0979-8A86-4D4C-ABB4-24317B13A118Q39919462-25140248-CA94-43EC-B8D7-7A899B9FF8FDQ40022357-2D599B91-BF73-4C40-9942-3427CC595EC9Q40314843-230B0E7B-56B1-4371-AF18-3F739EFE4EF2Q41134865-D42985C8-BFCD-4266-A755-D808E52B1040Q41174600-397D9726-9ABF-4E11-AFE7-A1891482A329Q41727863-87F41555-96C8-40D9-B74F-C67B072F79A8Q42812456-15D8D9FD-1C0F-42C2-B230-7B2500A867EAQ42816817-7D17EE60-0958-4161-AD19-D63A88ADC893Q42819449-B9EBDFA3-03C3-44E8-9CA0-2F0592AE3781Q44163463-63DC4635-D190-4A3A-B8F2-F1D6F9FEBEC7Q44177985-A5037324-5187-41CE-A084-3F361714A6B3
P2860
The human leukemia oncogene bcr-abl abrogates the anchorage requirement but not the growth factor requirement for proliferation
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
The human leukemia oncogene bc ...... requirement for proliferation
@en
type
label
The human leukemia oncogene bc ...... requirement for proliferation
@en
prefLabel
The human leukemia oncogene bc ...... requirement for proliferation
@en
P2093
P2860
P356
P1476
The human leukemia oncogene bc ...... requirement for proliferation
@en
P2093
J R McWhirter
M W Renshaw
P2860
P304
P356
10.1128/MCB.15.3.1286
P407
P577
1995-03-01T00:00:00Z